With the clock ticking on its blockbuster Humira patent in the US, AbbVie is reportedly in talks to sell the $5 billion women’s health portfolio it acquired from Allergan in order to pay off debt and focus on new areas.
Unnamed sources told Reuters that AbbVie is working with Morgan Stanley to auction off the portfolio, which includes the Lo Loestrin Fe birth control pill. The potential sale has reportedly attracted the likes of CVC Capital Partners, which the sources say is eyeing the unit for its portfolio company, Theramex.
Endpoints News has reached out to AbbVie to confirm the move and did not receive a response by press time.
This won’t be the first time executives look to sell the unit. In 2018, then-Allergan CEO Brent Saunders laid out plans to offload the company’s women’s health and infectious disease units. The following year, Saunders decided to hold on to the women’s health unit — several months before AbbVie plunked down $63 billion to buy out the company.
The deal gave AbbVie the Botox franchise and $16 billion in annual revenue to work with ahead of losing US patent protection for Humira in 2023. The immunology megablockbuster pulled in $16.1 billion in net sales last year alone. Since the buyout, AbbVie has been steadily shedding Allergan pipeline products, with the main focus on Botox.
Back in August, AbbVie bid adieu to the gene editing work with Editas it inherited in the buyout. And two months earlier, it swept out a collaboration deal with Assembly Biosciences.
Reuters reported that the women’s health portfolio generates a 12-month EBITDA of $500 million, and could be valued at 10 times that.